These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16110641)

  • 1. Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.
    Albertini MR; Hank JA; Sondel PM
    Cancer Chemother Biol Response Modif; 2005; 22():789-97. PubMed ID: 16110641
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
    Albertini MR; Gan J; Jaeger P; Hank JA; Storer B; Schell K; Rivest T; Surfus J; Reisfeld RA; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):278-95. PubMed ID: 8877722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
    Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
    Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical models for immunotherapy of melanoma.
    Reisfeld RA
    Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
    [No Abstract]   [Full Text] [Related]  

  • 5. Melanoma-associated antigens: prospects for clinical use.
    Lejeune FJ; Libert A
    Eur J Cancer Clin Oncol; 1985 Dec; 21(12):1433-8. PubMed ID: 3830723
    [No Abstract]   [Full Text] [Related]  

  • 6. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells.
    Dippold WG; Knuth A; Meyer zum Büschenfelde KH
    Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to monoclonal antibodies in melanoma: specific or non-specific?
    Knuth A
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1285-8. PubMed ID: 3830212
    [No Abstract]   [Full Text] [Related]  

  • 8. Ipilimumab, a human monoclonal antibody for treatment of unresectable or metastatic melanoma.
    Wilkes GM
    Oncology (Williston Park); 2011 Jul; 25(7 Suppl Nurse Ed):46-7. PubMed ID: 25373277
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of metastatic melanoma with CTLA4 antibodies].
    Hafner C
    Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523
    [No Abstract]   [Full Text] [Related]  

  • 10. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.
    Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF
    Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity unleashed in melanoma.
    Erdmann MK
    Lancet Oncol; 2010 Feb; 11(2):108-9. PubMed ID: 20152761
    [No Abstract]   [Full Text] [Related]  

  • 12. HMB-45: a clue to the biology of malignant melanoma?
    Wick MR
    J Cutan Pathol; 1991 Oct; 18(5):307-8. PubMed ID: 1761781
    [No Abstract]   [Full Text] [Related]  

  • 13. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
    Yamazaki N; Maeda Y
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
    [No Abstract]   [Full Text] [Related]  

  • 14. Human monoclonal antibodies.
    Kan-Mitchell J; Mitchell MS
    Prog Clin Biol Res; 1989; 288():85-94. PubMed ID: 2717643
    [No Abstract]   [Full Text] [Related]  

  • 15. Are we entering a new era in melanoma treatment? Lesson from ASCO 2011.
    Mouawad R; Spano JP; Khayat D
    Melanoma Res; 2011 Oct; 21(5):377-9. PubMed ID: 21900791
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
    Gajewski TF
    Pigment Cell Melanoma Res; 2010 Oct; 23(5):580-1. PubMed ID: 20609175
    [No Abstract]   [Full Text] [Related]  

  • 17. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
    Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
    Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
    Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
    Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
    Eklund JW; Kuzel TM
    Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.